Objective: To assess the cross-sectional association between multimorbidity and imaging biomarkers of brain pathology in the population-based Mayo Clinic Study of Aging (MCSA).
Multimorbidity has a prevalence of 20%-30% in the general population, 1 and increases with age from 55% to 98% among persons older than 60 years. 1 Multimorbidity is becoming the norm among adults in primary care settings, 2 mandating the need to investigate not only the causes, but also the association with future health outcomes. Multimorbidity is associated with an increased risk for hospitalizations and increased length of stay, worsening quality of life and physical functioning, polypharmacy, mild cognitive impairment, 3 and depression, resulting in significant economic costs for the health care system. 2 Several of the common chronic conditions that contribute to multimorbidity are established risk factors for mild cognitive impairment (MCI) or dementia (e.g., vascular diseases, cerebrovascular disease, depression, or chronic obstructive pulmonary disease). [3] [4] [5] [6] [7] [8] We hypothesized, therefore, that multimorbidity may also be associated with abnormal brain imaging findings that are characteristically present in persons with Alzheimer disease (AD) dementia, but this association has not been studied. Thus, the objective of this study was to determine the cross-sectional associations between multimorbidity and in vivo biomarkers of brain pathology (atrophy, increased amyloid accumulation, and reduced metabolism) assessed by MRI, 11 C-Pittsburgh compound B ( 11 C-PiB), and 18 fluorodeoxyglucose ( 18 F-FDG) PET in Mayo Clinic Study of Aging (MCSA) participants who were cognitively normal at time of imaging.
METHODS Study population. The MCSA study design and methodology have been presented in detail previously. 9, 10 Olmsted County, Minnesota, residents aged 70-89 years on the prevalence (index) date (October 1, 2004) were enumerated using Rochester Epidemiology Project (REP) 11 resources. An ageand sex-stratified random sample of eligible Olmsted County residents (without dementia, not terminally ill or in hospice) was invited to participate in person or by telephone. 9 To maintain the study sample size, we have ongoing recruitment using the same protocols as in 2004. MRI was offered beginning in 2005 to all MCSA participants and 11 C-PiB/ 18 F-FDG PET scans were offered beginning in 2009. The present study includes participants who were recruited between 2004 and 2011, were cognitively normal at time of MRI, and had information on multimorbidity at the time of imaging. Of these, 1,449 had MRI scans, 689 individuals also had 11 C-PiB, and 688 participants had 18 F-FDG PET scans.
Standard protocol approvals, registrations, and patient consents. All study protocols were approved by the Institutional Review Boards of the Mayo Clinic and the Olmsted Medical Center, and participants provided written informed consent before participation.
Identification of chronic conditions. Ascertainment of multimorbidity has been published. 3, 12 Briefly, the diagnostic indices of the REP medical records linkage system were searched electronically for each participant to identify the ICD-9 codes for 19 chronic conditions 13 associated with any health care visit within 5 years before the first imaging (i.e., 5-year capture frame). 12 These conditions were proposed by the US Department of Health and Human Services in 2010 to study multimorbidity. 13 We excluded dementia diagnoses ascertained through the MCSA study evaluation. A separate 5-year capture frame was created for the MRI scan date and for the 18 F-FDG/ 11 C-PiB scan date. A specific chronic condition was assigned to a participant if he or she received 2 ICD-9 codes for the given condition separated by more than 30 days within the 5-year capture frame. 3, 12 Seventeen (of the 19) chronic conditions were captured in the study sample: hyperlipidemia, diabetes mellitus, hypertension, cardiac arrhythmias, coronary artery disease, stroke, congestive heart failure, cancer, asthma, depression, substance abuse disorders (drugs and alcohol), chronic obstructive pulmonary disease, chronic kidney disease, arthritis, osteoporosis, schizophrenia, and hepatitis. In addition, the 6 most common dyads (any combinations of 2 of the 17 chronic conditions) were identified in persons with multimorbidity. 3, 12 Identification of MCI/dementia. Participants were evaluated by a nurse or study coordinator and a physician and underwent neuropsychometric testing by a trained psychometrist supervised by a neuropsychologist. 9, 10 Nine tests included in the neuropsychometric battery assessed performance in memory, language, executive function, and visuospatial skills cognitive domains. 9, 10, 14 The coordinator interview included ascertainment of demographic information, self-reported questions about memory to the participant, and administration of the Clinical Dementia Rating scale 15 and the Functional Activities Questionnaire to an informant. 16 The physician evaluation included a medical history review, administration of the Short Test of Mental Status, 17 and a complete neurologic examination. A diagnosis of MCI, 9, 16 dementia, 18 or normal cognition for each participant was made by consensus decision among the 3 evaluators using published criteria. A cognitively normal diagnosis was assigned to those who performed in the normal range relative to the normative data and did not meet criteria for MCI or dementia.
Participant information collected at the baseline evaluation included age, sex, educational attainment, body mass index (weight in kilograms divided by height in meters squared), and gait speed (meter/second); APOE genotyping was performed at baseline.
Acquisition of MRI measures. We performed MRI studies at 3T (Signa; GE Healthcare, Waukesha, WI) with an 8-channel phased-array head coil, acquiring both a 3D magnetizationprepared rapid-acquisition gradient echo (MPRAGE) sequence and a fluid-attenuated inversion recovery sequence. 19 From each participant's MPRAGE, we measured hippocampal volume (HV) using FreeSurfer software (version 5.3), which was then adjusted for total intracranial volume. 20 Cortical (0.10 mm) and subcortical infarctions (white matter [WM], central gray matter [GM], cerebellum, brainstem) were ascertained by experienced image analysts and confirmed by a radiologist. Technicians who performed the imaging analysis had no knowledge of the clinical characteristics of participants. FreeSurfer (v 5.3) was used to measure cortical thickness. An AD-signature cortical thickness measure 21 was computed by averaging the cortical thickness in the following regions of interest (ROIs): entorhinal, inferior temporal, middle temporal, and fusiform cortices. We defined an abnormal AD signature cortical thickness as less than 2.74 mm, corresponding to 90% sensitivity in AD dementia. 18 F-FDG PET and 11 C-PiB PET acquisition. PET images were acquired using a PET/CT scanner operating in 3D mode. 22 A CT image was obtained for attenuation correction. The 11 C-PiB PET scan consisted of four 5-minute dynamic frames acquired 40-60 minutes after injection. 23 Participants were injected with 18 F-FDG 1 hour after the 11 C-PiB scan and imaged after 30-38 minutes, for an 8-minute image acquisition of four 2-minute dynamic frames. 23, 24 An in-house fully automated image processing pipeline was used for quantitative image analysis for 11 C-PiB and 18 F-FDG. Each participant's PET images were registered to his or her MRI, which had been labeled with our parcellation atlas. 23 A 11 C-PiB PET meta-ROI retention ratio (with GM and WM sharpening, partial volume correction) was calculated from the median uptake over voxels in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/ precuneus ROIs normalized to the cerebellar GM ROI of the atlas. 22 An AD signature 18 F-FDG PET ratio (nonsharpened, non-partial volume corrected) was calculated in a similar manner based on glucose metabolic rates from an AD signature meta-ROI and consisted of the average bilateral angular gyri, posterior cingulate, and inferior temporal cortical ROIs from both hemispheres normalized to pons and vermis uptake. [25] [26] [27] We defined an abnormal 11 C-PiB-PET retention ratio (standardized uptake value ratio) as $1.40 and an abnormal AD 18 F-FDG-PET ratio as #1.32, corresponding to 90% sensitivity in AD dementia. 28, 29 Statistical analysis. Multimorbidity was defined as having 2 or more chronic conditions in the 5-year capture frame, and categorized as mutually exclusive categories of 0 or 1, 2, 3, and 4 or more conditions. There were only 68 participants with 0 chronic conditions; therefore individuals with 0 and 1 chronic conditions were combined as the reference group.
We examined the cross-sectional association of multimorbidity with the dichotomous imaging measures (i.e., abnormal 11 C-PiB PET, abnormal AD signature 18 F-FDG PET [hypometabolism], and abnormal AD signature cortical thickness from MRI, and presence of cortical infarctions [cerebrovascular disease]) using multivariable logistic regression models (odds ratios [ORs], 95% confidence intervals [CIs]) adjusted for age, sex, education (basic model), and APOE e4 allele (full model). Examination of the residuals of regression of multimorbidity on the continuous MRI and PET imaging measures (i.e., AD signature cortical thickness, AD signature 18 F-FDG PET ratio, 11 C-PiB PET meta-ROI retention ratio, and HV) suggested a linear association. Therefore, we also used multivariable linear regression models to examine the associations (b coefficients, 95% CIs) of multimorbidity with imaging biomarkers in the basic and full models as above. Results from both logistic and linear regression were similar for AD signature cortical thickness, AD signature 18 F-FDG PET ratio, and 11 C-PiB PET meta-ROI retention ratio; thus, only the estimates from logistic regression analysis are presented in the tables. Potential effect modification by sex, education, and APOE e4 allele status was also examined.
In addition, we examined the association of the most common chronic conditions (frequency higher than 5%) and the most common dyads of chronic conditions with imaging biomarkers using multivariable logistic regression models. All analyses were considered significant at p , 0.05, and were performed using Stata/IC statistical software version 12.1 (StataCorp LP, College Station, TX) and SAS statistical software version 9.3 (SAS Institute, Cary, NC).
RESULTS
Population characteristics. Among 1,449 cognitively normal MCSA participants (mean age 79 years; 50.9% men), 1,237 (85.4%) had multimorbidity ($2 chronic conditions; table 1). Compared to MCSA participants who did not participate in imaging studies, participants who underwent imaging performed better on cognitive tests (global composite scores) from neuropsychometric testing, had a lower frequency of diabetes mellitus or hypertension, and a higher frequency of men, but did not differ in age or frequency of APOE e4 allele.
There were no differences in the frequency of multimorbidity or APOE e4 allele by sex (table 1) . Mean age at imaging and frequency of obesity increased with increasing number of chronic conditions; the inverse was observed for gait speed (table 2) . APOE e4 genotype was not associated with the number of chronic conditions. Association of multimorbidity with imaging biomarkers.
The frequency of abnormal AD cortical thickness and abnormal 18 F-FDG-PET increased with increasing number of chronic conditions; a similar pattern was not observed for abnormal 11 C-PiB-PET (table 2) . The frequency of cortical infarcts was highest with severe multimorbidity ($4 chronic conditions).
In multivariable analyses, multimorbidity ($2 conditions) was associated with abnormal 18 F-FDG-PET (hypometabolism) and abnormal AD signature cortical thickness, but not with abnormal amyloid (table 3) ; adjustment for APOE e4 did not change the estimates. Estimates were strongest for severe multimorbidity ($4 chronic conditions) and patterns of association were similar for analyses using continuous imaging measures. An increasing number of chronic conditions was associated with presence of cortical infarcts (OR 1.30; 95% CI 1.16 to 1.44; p , 0.001; per unit increase in chronic conditions) and lower hippocampal volume (b 5 20.021; 95% CI 20.041 to 20.001; p 5 0.04) (results not shown in tables).
We observed interactions between sex and the number of chronic conditions (as a continuous measure) in regard to the association with abnormal 11 C-PiB PET (p 5 0.037) and between sex and multimorbidity ($2 chronic conditions) in regard to the abnormal 18 F-FDG-PET (p 5 0.0496). In sex-stratified analyses, the associations for abnormal 11 C-PiB PET were not significant in men or in women; however, the OR of an abnormal 18 F-FDG was stronger in women with multimorbidity (OR 6.03; 95% CI 1.40 to 26.03) than in men with multimorbidity (OR 1.38; 95% CI 0.67 to 2.85) compared to those with 0-1 conditions (table e-1 on the Neurology ® Web site at Neurology. org). Failure to detect a statistically significant association in men may relate to small sample sizes in some cells, and the wide CI in women raises questions about the precision of the estimates. There were no interactions of multimorbidity with sex in regard to AD signature cortical thickness and hippocampal volume, or with education and APOE e4 allele status in regard to any of the imaging biomarkers studied.
Several of the most frequent single chronic conditions were associated with abnormal AD signature cortical thickness or abnormal 18 F-FDG-PET in multivariable models (e.g., hypertension, arthritis, diabetes mellitus, cancer, arrhythmia, coronary artery disease) (table 4) . However, residual confounding could be present since these models do not take into account coexisting chronic conditions as covariates in the model. Most of the 6 common pairs (dyads) were associated with abnormal AD signature cortical thickness or abnormal 18 F-FDG-PET but not with abnormal amyloid in multivariable analyses (table 5) . The associations with abnormal 18 F-FDG-PET were stronger in dyads that included diabetes mellitus. DISCUSSION In this sample of cognitively normal elderly individuals, we investigated the cross-sectional associations of multimorbidity with known AD-related neuroimaging measures including brain cortical thickness, amyloid accumulation, and hypometabolism. Multimorbidity ($2 chronic conditions) was associated with hypometabolism and decreased cortical thickness in AD signature regions, and this association was likely driven by the strong associations observed for severe multimorbidity (i.e., $4 chronic conditions). Failure to observe associations of multimorbidity with increased amyloid suggests that the observed associations with other biomarkers of brain pathology may involve mechanisms independent of amyloid deposition. This pathology may be present before symptomatic evidence of cognitive impairment.
Although the exact mechanism for the association of multimorbidity with neuroimaging measures of neurodegeneration cannot be delineated in the current study, we hypothesize that known mechanisms governing the association of chronic diseases, specifically, vascular conditions such as diabetes 30, 31 or vascular disease, 29,30,32 with antemortem 30,31 imaging or Table 2 Characteristics of participants at baseline MRI by number of chronic conditions postmortem 32 biomarkers could be involved in these pathologic processes. In the present study, the most common dyads (i.e., hypertension and hyperlipidemia, hypertension and arthritis, hyperlipidemia and arthritis, hypertension and diabetes mellitus, cancer and hypertension, hyperlipidemia and diabetes mellitus) that were associated with hypometabolism and decreased cortical thickness in AD signature regions all included vascular conditions. This is consistent with dyads previously found to be associated with risk of incident MCI in the MCSA cohort. 3 A second hypothesis is that the aggregate effect of multiple co-occurring chronic conditions on brain pathology may differ from the simple summation of their individual effects-as suggested for example by investigators 32 for the co-presence of multiple vascular risk factors and their aggregate effect on brain pathology. As such, the insight provided by the association of multiple co-occurring conditions (i.e., multimorbidity) with antemortem brain pathology is informative and relevant for early detection and intervention for those at increased risk of brain pathology.
The underlying mechanism for the interaction of sex with FDG metabolism is unclear. However, it suggests that multimorbidity may be differentially associated with brain pathology in men vs women as observed for other conditions. For instance, cardiac disease was associated with nonamnestic MCI in women but not in men, 33 and atrial fibrillation with cognitive decline in women but not in men. 34 The interaction may also be due in part to different combinations of medical conditions reported in men vs women, 35 or to sex differences in cerebral glucose metabolism. The borderline interaction and wide CI in estimates for women suggest a low precision, and these cross-sectional findings should be regarded with caution. In particular, higher estimates of brain hypometabolism reported in men 30 and a stronger association of multimorbidity with MCI in men than women 3 would suggest a stronger association of multimorbidity with brain hypometabolism in men.
Our findings that multimorbidity is not associated with biomarkers of amyloid deposition are in agreement with previous studies suggesting that Table 3 Association between multimorbidity and abnormal imaging biomarkers in cognitively normal individuals: Mayo Clinic Study of Aging cardiovascular disease may not directly affect amyloid accumulation. 32, 36 However, vascular disease could have effects on WM, and likely is associated with cortical atrophy. 32 In a clinicopathologic imaging study, 37 subcortical vascular pathology and atherosclerosis contributed to lower cortical GM volume after AD pathology was considered, further suggesting the importance of vascular pathology to neurodegenerative processes. Diabetes mellitus and hypertension have also been associated with brain pathology such as ischemic lesions or atrophy in imaging studies. 31 These conditions could cause small vessel disease and other cerebrovascular damage or promote neurodegenerative processes through interactions at the cellular level with neurons or synapses. By contrast, while the exact etiology of brain amyloidosis is unclear, it is multifactorial and includes genetics (APOE e4), inflammation, oxidative damage/stress, and small or large vessel disease. The relative contribution of vascular disease to development of amyloidosis is unclear, but may explain the lack of an association of multimorbidity, which primarily consisted of vascular conditions, with amyloid accumulation. We did not observe any confounding or effect modification by APOE e4 that could explain the lack of association of multimorbidity with amyloid accumulation.
Limitations of the study warrant consideration. Because of its cross-sectional design, we cannot assess causality. However, longitudinal follow-up of the cohort will enable us to identify the effects of multimorbidity on changes in imaging biomarkers. The exact mechanism of the association of multimorbidity with neuroimaging measures of neurodegeneration cannot be delineated in the current study and findings may not necessarily be generalized in older populations with different distribution and prevalence of chronic conditions. Multimorbidity was assessed later in life and those with earlier onset of comorbidities who had more severe disease may have died or declined to participate; this would result in an underestimate of the associations toward the null, i.e., we could expect even stronger estimated associations had these participants been included. In addition, participants with imaging studies might not be completely representative of the total MCSA population; nonparticipants in imaging studies had a higher frequency of diabetes and hypertension, but did not differ in age or APOE e4 allele. These differences in the frequency of chronic conditions may bias the association between multimorbidity and imaging biomarkers toward the null. We cannot account for the effects related to efficiency of management of multimorbidity, or adequacy of control of conditions such as diabetes or blood pressure on the observed associations.
The study has several important strengths. The population-based design reduced the potential for selection bias that could occur from recruiting volunteers or studying clinical cohorts only. The state-ofthe-art multimodal imaging studies used to ascertain brain pathology provide reliable measures of brain pathology and thereby yields valid estimates of associations. In addition, multimorbidity was assessed using the REP medical records linkage system and was not dependent on self-report and eliminated recall bias.
Given that many of the predictors of chronic conditions are modifiable, preventive strategies targeting the decrease or postponement of multimorbidity may be beneficial for neurodegeneration and neuronal injury that are independent of Alzheimer pathology.
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